Sharon Sha, MD
Behavioral Neurology & Neuropsychiatry · Stanford, CANPI 1225299027
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,700 of the $8,078 with a category attached, or 70.6%. 5 manufacturers reported payments, led by Eisai Inc. at 59.8% of the total. Reporting peaked in 2024 at $4,746 and has fallen 99.4% since, to $29 in 2025.
Across 20 payments — averaging $403.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$5K
- Biogen$2K
- Genentech USA, Inc.$1K
- Medtronic$169
- Genentech, Inc.$29
Across 264 payments — averaging $24,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2.3M
- Eisai Inc.$1M
- Novartis$841K
- Eli Lilly$781K
- Genentech, Inc.$682K
- Janssen Research & Development, LLC$566K
- plus $188K from 4 others
What the payments were for
- Consulting fees$5,70071%
- Travel & lodging$1,62020%
- Food & beverage$7589%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $4,833 |
| Biogen | 14 | $2,027 |
| Genentech USA, Inc. | 1 | $1,020 |
| Medtronic | 1 | $169 |
| Genentech, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$4,680
- Activase$1,020
- Cathflo Activase$1,020
- TNKase$1,020
- OCREVUS$1,020
- Non-Covered Product$1,020
- ACTIVA$169
How this compares
Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $230,236 |
| Rivastigmine | 77 | $13,366 |
| Memantine Hcl | 35 | $3,836 |
| Donepezil Hcl | 207 | $2,936 |
| RivastigmineRivastigmine Tartrate | 33 | $2,258 |
| Sertraline Hcl | 150 | $724 |
| Mirtazapine | 44 | $544 |
| Escitalopram Oxalate | 48 | $507 |
| Donepezil Hcl OdtDonepezil Hcl | 20 | $326 |
| Risperidone | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Other behavioral neurology & neuropsychiatry in Stanford
- Victor HendersonStanford$32
- Collins LiuSan Diego$37K
- Seyed SajjadiOrange$10K
- Neda HeidariOxnard$8K
- Michael FrazierWestminster$8K
- Gabriel LegerSan Diego$4K
- Paramjit SinghChico$4K
- Peter WagnerRancho Mirage$666
- Balasubramaniam GulasekaramCerritos$310
- Anish DhamijaSan Diego$57
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.